Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type

ANIKA THERAPEUT   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2024202320222021202020192018201720162015
Period End Date12/31/202412/31/202312/31/202212/31/202112/31/202012/31/201912/31/201812/31/201712/31/201612/31/2015
Product revenue119.91166.66156.24147.79130.46114.51105.53107.78102.9387.70
Licensing, milestone and contract revenue----------0.100.025.640.455.30
Total Revenues119.91166.66156.24147.79130.46114.61105.56113.42103.3893.00
Cost of product revenue43.9163.5762.6664.8561.4328.7531.2827.3624.0321.05
Gross Profit76.00103.0993.5882.9469.03----------
Goodwill impairment--------42.52----------
Research & development25.5432.6928.1827.3323.4316.6718.1918.7910.738.99
Selling, general & administrative55.5695.8584.7974.1060.0634.9534.3421.5418.0114.83
Restructuring charges--------------------
Acquisition-related expenses--------------------
Impairment of intangible assets--(62.19)----------------
Litigation settlement costs--------------------
Change in fair value of contingent consideration------21.1028.67----------
Total Operating Expenses81.10190.73112.9880.3397.3580.3683.8167.6952.7744.87
Operating Income (Loss)(5.10)(87.64)(19.40)2.62(28.32)34.2521.7545.7350.6148.13
Interest income, net2.342.310.65(0.19)(0.30)1.871.460.470.260.12
Income (loss) before income taxes(2.76)(85.33)(18.75)2.43(28.62)36.1223.2146.2050.8748.25
Current: Federal4.043.151.010.490.366.254.7812.6114.9814.57
Current: State1.370.310.29(0.64)(1.97)1.881.642.743.273.64
Provision for income taxes6.06(2.66)(3.89)(1.71)(4.64)8.934.4914.3918.3217.50
Deferred: Federal--(5.05)(3.24)(0.55)(1.98)1.09(0.99)(0.43)(0.07)(0.37)
Deferred: State--(1.42)(1.26)(0.43)(1.07)0.32(0.15)(0.07)(0.08)(0.03)
Deferred: Foreign0.230.03(0.77)(0.75)(0.03)(0.81)(1.20)(0.50)(0.07)(0.56)
Current- Foreign0.420.310.100.170.050.200.410.030.300.25
Benefit from release of valuation allowance--------------------
Benefit from release of valuation allowance: Federal--------------------
Benefit from release of valuation allowance: State--------------------
Loss from continuing operations(8.83)------------------
Loss from discontinued operations(47.56)------------------
Income Before Extraordinary Income & Accounting Change--------------------
Net Income (Loss) Available to Common Shareholders(56.39)(82.67)(14.86)4.13(23.98)27.1918.7231.8232.5530.76
Basic: Income (loss) before cumulative effect of change in accounting principle--------------------
Basic: Continuing Operations(0.60)------------------
Basic: Discontinued Operations(3.23)------------------
Basic: Net income per share(3.83)(5.64)(1.02)0.29(1.69)1.931.302.182.222.06
Diluted: Income (loss) before cumulative effect of change in accounting principle--------------------
Diluted: Continuing operations(0.60)------------------
Diluted: Discontinued operations(3.23)------------------
Diluted net income per share(3.83)(5.64)(1.02)0.28(1.69)1.891.272.112.152.01
Basic weighted average common shares outstanding14.7214.6614.5614.4014.2214.1214.4414.5814.6814.93
Diluted weighted average common shares outstanding14.7214.6614.5614.6314.2214.3714.6915.0715.1215.32